JPRN-jRCT2080220660UnknownPhase 3
Randomized trial of oxaliplatin plus S-1 (SOX) versus S-1 alone in patients with gemcitabine-refractory pancreatic cancer
Trial Snapshot
- Phase
- Phase 3
- Sponsor
- Yakult Honsha Co.,Ltd.
- Enrollment
- 240
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 20age old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- •Histologically or cytologically proven pancreatic adenocarcinoma or adenosquamous carcinoma
- •Gemcitabine refractory
- •Taking orally
- •ECOG performance status (PS) :0-1
- •Measurable metastatic disease based on RECIST criteria
Exclusion Criteria
- •Prior treatment with platinum- or fluoropyrimidine -agent
- •Prior treatment with radiotherapy
Investigators
Similar Trials
Unknown
Phase 3
A Randomized Phase III Trial of SOX/Bevacizumab versus FOLFOX/Bevacizmab in Treating Patients with Metastatic Colorectal Cancer (SOFT).JPRN-jRCT1080220674Taiho Pharmaceutical Co., Ltd.500
Unknown
Phase 3
Randomized phase III study of S-1 plus oxaliplatin compared with S-1 plus cisplatin as first-line therapy for advanced or recurrent gastric cancerAdvanced or recurrent gastric cancerJPRN-jRCT2080220988Yakult Honsha Co.,Ltd.
Completed
Phase 3
Phase III Adjuvant Chemotherapy of S-1 plus Oxaliplatin for Colorecrtal Cancer (ACTS-CC 02)JPRN-jRCT1080221040Taiho Pharmaceutical Co., Ltd.1,200
Unknown
Unknown
A phase 1/2 trial of Oxaliplatin(L-OHP) + S-1 in patients with previously untreated advanced colorectal cancerColorectal cancerJPRN-jRCT2080220116Yakult Honsha Co.,Ltd.
Completed
Phase 1
Phase I Trial of S-1 and Weekly Oxaliplatin in Combination with Radiotherapy for Neoadjuvant Therapy of Locally Advanced Rectum CancerRectal cancer of Stage II or III with T4 or lateral lymph node metastasis at the pre-operative diagnosisJPRN-UMIN000002845ational cancer center hosital12